Hello, and welcome to the 31st Deutsche Bank Depositary Receipts Virtual Investor Conference, DBVIC. My name is Zafar Aziz from the DR Investor Relations Advisory Team at Deutsche Bank. I am pleased to announce that our next presentation will be from Radiopharm. Please note all of today's presentations will be recorded and can be accessed via the Deutsche Bank website, adr.db.com. At this point, I am very pleased to welcome our speaker from Radiopharm.
Good morning. Hi, everybody. Welcome. This is Dimitris Voliotis from Radiopharm, and I am happy to give an update on our assets in the pipeline. This is the notice and disclaimer. So, jumping into the highlights, we currently have a platform of two diagnostics and four therapeutics, a very differentiated pipeline. We have a number of near-term catalysts in 2027. The two imaging agents are completed successfully with phase II and phase I studies respectively, and we have an ongoing partnering process here. The four therapeutic trials are shown below. One is targeting HER2, RAD202, the other one PD-L1, RAD204, B7-H3, RV01, RAD402, KLK3. Here is another overview of the pipeline. At the bottom again, RAD101 and RAD301 are the two imaging agents for which we successfully completed a phase I and a phase IIb respectively. Those are done, and we are in the process, as I said, of engaging partnering discussions.
So let's go to the therapeutic program, starting with RAD202. That is a HER2-targeted radiotherapy, and obviously, we are trying to bring this different mechanism of action, radiotherapy, to the HER2 indications. Not just breast, but of course, particularly important for breast. HER2 is one of the most established targets. It is a broad population. If you look at how the expression is between HER2 low, between HER2 IHC, or the gene expression, and the post-HER2, this is a very diverse and large opportunity and indication. And we are trying to introduce best-in-class radiotherapy with a validated biology frame around that. This is our compound. It is a nanobody. So it is a small molecule, about 15 kilodalton molecular weight, with nanomolar affinity. It is targeting a distinct epitope versus trastuzumab, so there is no overlap.
The currently approved treatments in this indications, HER2, are antibodies and ADCs, as shown here, which are limited, of course, by resistance and systemic toxicity. By introducing radiotherapy, we are bringing in a different mechanism in a radiation-sensitive disease with no cross-resistance with those established antibody and antibody drug conjugate treatments. Looking at the real-world situation in terms of efficacy, after HER2, we are seeing around 10%-25% response rate in three to five months PFS. The trial is ongoing and recruiting very well. We are currently in dose level 4. We are planning to enroll four patients here, so we have three of those enrolled. Dose levels 1, 2, and 3 have been completed successfully. We have tumor uptake confirmed. We have great safety, and we have no dose-limiting toxicities at this point. The current dose level is 180 millicurie.
The next dose level, which still has to be approved, of course, in terms of the number that you can see here, we are targeting somewhere in the 240 millicurie vicinity. What we are seeing in terms of tumor response, a couple examples here. There is a patient with an ampullary carcinoma here, and you see that a -11% decrease or 11% decrease in tumor size that is changing, getting better over time. This is still officially per RECIST stable disease, but you can see that we see an increase in the response, actually. In the current, in the fourth dose level, it is a little early to say what the efficacy is going to be at the end of the cohort, but we do see disease stabilization in patients who were progressive after a number of previous therapies here with 0% or -9% tumor size.
One of the questions that, of course, is obvious with a small molecule radioligand therapy is always going to be safety, and then in particular, how the renal safety is. If we look at the safety overall, that is shown here. You can see that the adverse events are mainly grade 1 and 2. If you look at the lower box, we have very few, a total of just five grade 3 treatment-emergent adverse events, no grade 4 or 5, and no SAEs. In terms of dose-limiting toxicity, as I already said, there is none thus far in any of the cohorts. So, from a safety perspective, a very well-tolerable regimen. As I mentioned earlier, we have, of course, when we look at small molecules, always the question of renal toxicity, and we have not observed any creatinine increase or eGFR decrease in those patients over time.
As you can see here in the table, the patients are very much stable. So, it is not just very well tolerable in terms of the adverse events that we have been observing, but also when you look specifically at the excretion mechanism, the kidney, we do not see any adverse effects here either. So, from, let us say, a broader investment case perspective, this is targeting one of the largest and most validated oncology indications, targets. We are introducing a new mechanism of action. It is still, obviously, while we are in dose escalation, early to conclude, but we think we are trending favorably towards the standard of care, as shown here.
We think we are going to be able to show you when we are done with the dose escalation and we have more patients at the highest dose levels that we have toxicity that will be sufficient to meet the standard of care. As I said earlier, it is still early days. We are still in the dose escalation, but what we see so far is certainly very promising. Next target is PD-L1. The agent is RAD204, which is, of course, PD-L1, a validated immuno-oncology target. We have a first-in-class PD-L1 targeted radiotherapy drug with this here. You are, I am sure, aware of the fact that radiotherapy and targeted immunotherapy go together very well. There are numerous publications that have shown that introducing radiotherapy really augments the anti-tumor T-cell response specifically. So, combining these two mechanisms, radiotherapy and targeted immunotherapy, makes a lot of sense.
Our lead indication is post-IO non-small cell lung cancer, but not only non-small cell lung cancer. We are in the study recruiting across different tumor types, as long as they are PD-L1 expressing. We are expanding a proven target into a new therapeutic modality with radiotherapy. It is the same format as shown before. It is a nanobody with sub-nanomolar affinity, a distinct epitope again. From the framing of the therapeutic situation today, we have, of course, established antibodies that have shown very good activity, but we are not curing patients. At the end of the day, all these patients relapse, or most of them relapse. New therapies that are addressing this particular target are necessary. Again, we are introducing radiotherapy as a distinct mechanism in radiosensitive diseases.
The benchmark to beat that we are looking at in post-IO non-small cell lung cancer is 20%-25% overall response rate and four to six months PFS. Again, in the blue box below, some of the background for the mechanism, combining radiotherapy and IO leads to what is called accelerated and brake release at the same time. You are releasing tumor antigens, priming tumor-specific T-cell response, and with the PD-L1 blockade, removing the inhibition of the T-cells that sometimes radiotherapy induces. These two go together very well as a mechanism of action. We are currently in dose level 3 here. We have successfully completed dose level 1 and 2. We have observed disease responses here. One patient with a partial response, 43% reduction in tumor size, shown here on the left side. That is a patient with non-small cell lung cancer.
Patient did not experience a DLT while in the study. Currently has a PFS still ongoing of 9.5 months, experienced a partial response. We have another patient here who showed a decrease initially in tumor size of 12%, - 12% tumor size, but ultimately did experience a new lesion, which constituted progression of the disease. This is the patient with the PR. This is a non-small cell lung cancer patient after multiple prior therapies. As you see here, external beam, chemotherapy, and checkpoint inhibitors. On the right side, you see the comparison of the baseline versus first, second, third dose. You can see that there is an obvious decrease in the tumor, which is on the left side of this image, going from the top to the bottom.
This is a confirmed partial response with 43% tumor size reduction, PFS of 9.5 months. Looking at all patients now combined across the study, you can see here that we have three patients with a pretty long treatment duration here, 170, 168, and 195 days. Those are not necessarily tied to a status of PR, although one was a PR. That is the one that I showed you earlier here, the patient in green. But we do have two more patients with a long treatment duration that stayed stable for a longer period of time without progressing. For a dose escalation study, starting with 30 millicurie, which is obviously a low dose, those are really pretty good treatment durations. Here, I have a different view of the same study population. On the left side is the waterfall plot. You can see the best response.
On the right side, the spider plot, you see the response over time, and you can see that both the PR, but also those patients who are formerly a stable disease between -30% and +20%, some of them had experienced a really long disease stabilization, with some tumor shrinkage, some with a tumor shrinkage, some with a small increase, but still stable disease. We see promising evidence of anti-tumor activity in an early dose escalation stage. We believe that with the currently observed results, we are still tending towards better than standard of care, with officially a response rate of 50% and a PFS between these patients of 6.7 months. Very happy with what we see. Needs to be confirmed, of course, with additional patients, and the study is ongoing in the third cohort.
Just to summarize, this is one of the largest, if not the largest, immuno-oncology target with a very significant market size in the U.S. and worldwide. Targeted therapy introduces a new principle, which from a mechanism of action perspective, is very logical and has been shown to be synergistic radiotherapy and targeted immune therapy. We have the opportunity here to continually optimizing our platform this way. We have early clinical signals observed at dose level 3, and with this particular compound, we are first in class. The two other compounds that we have in our therapeutic pipeline are antibodies. One is targeting B7-H3, which, as you know, is one of the most promising, important emerging targets in AUC and Radiopharm. We are currently in dose level 2. The study is recruiting very well. This is a U.S.-based study.
RAD402 is a study that is recruiting in Australia right now, that is also recruiting very well, obviously patients with prostate cancer. This is a different target from PSMA. There is no overlap. PSMA KLK3 is expressed very broadly in the prostate and prostate cancer patients. As I said, both these programs are using antibodies as the vector for the therapy. One is using, Lutetium-177 is the warhead, and the other one is Terbium-161. Final overview of the pipeline and summary of what I was trying to convey here. We have two imaging modalities, RAD101, RAD301. Imaging trials completed successfully. We are in the process of partnering these two. This, of course, would provide upfront and milestones, non-dilutive monetization of the assets. We are not planning to further ourselves so much, continue those. We will focus our resources on the therapeutic compounds shown below.
We will have, in the first and second half of next year, a number of milestones and inflection points for RAD202. We hope that we will be able to finish the dose escalation, of course, and then for RAD202 and RAD204, enroll patients at a higher dose and increase our perspective on the therapeutic activity, on the efficacy. Similarly for RV01, which is the B7-H3 and RAD402, the KLK3 targeting antibody, be able to present further update on the clinical progress that we have. Those are my slides. Thank you very much for your attention, and I am happy to take questions. The question, one question is, which clinical and regulatory milestones should investors view as value inflection points?
Obviously, for the next year, we hope that we will be able to get to the final dose for RAD202 and present additional updates on the clinical activity, similar for RAD204, which means that we would then go into an expansion of the phase I and be able to really understand the clinical efficacy at the recommended phase II dose. For RV01 and RAD402, we will continue the dose escalation and update on the observed clinical activity. Let me go through the questions here. There is one question around the diagnostic study for RAD202, where we got FDA alignment that we can proceed with a one study. Obviously, this is a very significant saving in both cost and time. We anticipate that the phase III, as we communicated in the press release, will be about 280 patients.
Typically, the standard FDA approach is that we need two well-controlled clinical phase III trials, and obviously, this would be simply doubling that, and a very significant milestone for us, a validation of our phase II data, and the fact that we were able to get an agreement with the FDA on that phase III. Without putting a specific number behind it, but it is clearly half of two studies, so it is a very significant saving, and it would certainly be a significant saving in time and budget. More questions around RAD101. We have communicated that we will expect the specificity and sensitivity endpoints by the end of the year. We are on track for that. I just wanted to say that sensitivity and specificity are not the primary endpoints of this phase IIb study.
The phase IIb study that we first published in June, the primary endpoint is concordance between MRI and PET, which is really meant to validate the PET as opposed to the standard of care. We will get the secondary endpoint, sensitivity, specificity, by the end of the year. Those two endpoints, sensitivity, specificity, which are diagnostic accuracy, will of course be the subject of the phase III that we just got agreement with the FDA on. Question around Terbium for RAD402. Terbium is a very interesting emerging isotope in radioligand therapy, based on the fact that with the Auger and conversion electrons, we have additional mechanisms that target beyond the beta. Compared to Lutetium, when combined with PSMA peptides, it has been shown that it has more activity at the same dose level because of the added targeting, micro-targeting of the conversion and Auger electrons.
Just going through the questions here. Give me a second. Another question on RAD101. Where could this make the biggest difference when MRI is inconclusive? I did not have slides here, because, as I said, from a development perspective, with our own efforts, we will focus on the therapeutic programs. But the truth is that RAD101 has the potential to target a very important medical problem, which is patients with non-brain metastases who have received radiotherapy, specifically stereotactic radiosurgery or stereotactic radiotherapy, and have suspected but not proven relapse. MRI is not good in detecting relapse or progression after SRS and SRT. The PET comes in to be able to identify those patients that on the MRI have equivocal findings or inconclusive findings as confirming progression or radionecrosis. This would be addressing a very, very significant clinical problem. Okay, I think I went through the questions.
Just making sure there's one that I completely skipped. Okay. I think we're okay from a Q&A perspective. Any last minute? If not, then thank you for your attention, and obviously, we're open for any additional questions by email or otherwise. Thank you very much.